Literature DB >> 21182660

Correctable visual impairment among people with diabetes in Hong Kong.

Mavis My Fung1, Maurice Kh Yap, Karen Ky Cheng.   

Abstract

BACKGROUND: the prevalence of visual impairment is known to be higher in a diabetic population than in a non-diabetic population. How much of this visual impairment may be attributed to uncorrected refractive error is unclear. This study examined the prevalence of visual impairment in a Hong Kong diabetic population to determine the proportion of the visual impairment that could be corrected with prescription spectacles.
METHODS: patients with type 2 diabetes mellitus (T2DM) were recruited as subjects for this study. All subjects underwent a standardised diabetic retinopathy screening that included measurement of presenting distant vision, biomicroscopic examination of the anterior eye and a retinal examination. For those subjects whose visual acuity was worse than 6/9.5, autorefraction was performed. In this study, we classified visual impairment into three categories: no visual impairment (visual acuity in the better eye better than or equal to 6/18), mild visual impairment (visual acuity in the better eye between 6/18 and 6/60) and severe visual impairment (visual acuity in the better eye less than or equal to 6/60).
RESULTS: for the 2,301 subjects who participated in this study, the mean age at examination was 61.4 ± 10.5 years (range, 23 to 92 years). Regarding visual acuity, 11.3 per cent (259/2,301) of subjects had visual impairment with 10.6 per cent being mild (244/2,301) and 0.7 per cent severe (15/2,301). After correction with a prescription determined by autorefraction, the prevalence of visual impairment dropped to 4.0 per cent (91/2,301). Nearly 70 per cent (168/259) of visual impairment was correctable by prescription spectacles and 21.6 per cent (56/259) of subjects were likely to benefit from cataract surgery.
CONCLUSION: for our sample of diabetic patients, nearly 70 per cent of the visual impairment could be remedied by a spectacle correction. In the care of the diabetic eye, eye-care providers should not focus solely on diabetic retinopathy. The quality of life in people with T2DM can be improved simply by eliminating uncorrected refractive errors.

Entities:  

Mesh:

Year:  2010        PMID: 21182660     DOI: 10.1111/j.1444-0938.2010.00539.x

Source DB:  PubMed          Journal:  Clin Exp Optom        ISSN: 0816-4622            Impact factor:   2.742


  5 in total

1.  Prevalence and associated risk factors of undercorrected refractive errors among people with diabetes in Shanghai.

Authors:  Mengjun Zhu; Xiaowei Tong; Rong Zhao; Xiangui He; Huijuan Zhao; Jianfeng Zhu
Journal:  BMC Ophthalmol       Date:  2017-11-28       Impact factor: 2.209

2.  The Prevalence and Causes of Visual Impairment in Type 2 Diabetes Mellitus in Northeast China.

Authors:  Liang Wen; Yu Wang; Zhong Lin; Feng Hua Wang; Xiao Xia Ding; Dong Li; Kemi Feng; Yuan Bo Liang; Dong Xiao Zhang; Yu Dou; Gang Zhai
Journal:  J Ophthalmol       Date:  2020-11-29       Impact factor: 1.909

3.  Prevalence and causes of low vision and blindness in a Chinese population with type 2 diabetes: the Dongguan Eye Study.

Authors:  Ying Cui; Liang Zhang; Min Zhang; Xiaohong Yang; Lixin Zhang; Jian Kuang; Guanrong Zhang; Qingyang Liu; Haike Guo; Qianli Meng
Journal:  Sci Rep       Date:  2017-09-11       Impact factor: 4.379

4.  Hyderabad Ocular Morbidity in Elderly Study (HOMES) - Rationale, Study Design and Methodology.

Authors:  Srinivas Marmamula; Navya Rekha Barrenkala; Rajesh Challa; Thirupathi Reddy K; Shashank Yellapragada; Satya Brahmanandam M; David S Friedman; Rohit C Khanna
Journal:  Ophthalmic Epidemiol       Date:  2019-10-28       Impact factor: 1.648

5.  Prevalence and risk factors for visual impairment among elderly residents in 'homes for the aged' in India: the Hyderabad Ocular Morbidity in Elderly Study (HOMES).

Authors:  Rohit C Khanna; David S Friedman; Srinivas Marmamula; Navya Rekha Barrenakala; Rajesh Challa; Thirupathi Reddy Kumbham; Satya Brahmanandam Modepalli; Ratnakar Yellapragada; Madhuri Bhakki
Journal:  Br J Ophthalmol       Date:  2020-03-25       Impact factor: 4.638

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.